Photo by nci from unsplash
Novel diabetes agents (glucagon-like-peptide-1 receptor agonists, GLP-1 RA and sodium-glucose cotransport-2 inhibitors, SGLT2i) reduced death and cardiovascular events in randomized trials, but uptake in clinical practice has lagged. We assessed… Click to show full abstract
Novel diabetes agents (glucagon-like-peptide-1 receptor agonists, GLP-1 RA and sodium-glucose cotransport-2 inhibitors, SGLT2i) reduced death and cardiovascular events in randomized trials, but uptake in clinical practice has lagged. We assessed the unrealized potential for reduction in mortality
Keywords:
potential unrealized;
diabetes agents;
unrealized cardiovascular;
novel diabetes;
benefit novel;
cardiovascular benefit
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!